Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 28

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 28
---
 production facilities for our Therapeutic DNA Production Services; |

| · | demand for Therapeutic   
 DNA Production Services; |

| · | demand for DNA Tagging 
 Services;              |

| · | demand for MDx Testing 
 Services;              |

| · | our expectations concerning                                                                                
 existing or potential development and license agreements for third-party collaborations or joint ventures; |

<div align='center'>11</div>

| · | regulatory approval and                                                                                              
 compliance for our Therapeutic DNA Production Services, upon which our business strategy is substantially dependent; |

| · | the effect of governmental 
 regulations generally;     |

| · | our expectations of when                                                          
 regulatory submissions may be filed or when regulatory approvals may be received; |

| · | our expectations concerning              
 product candidates for our technologies; |

| · | our                                                                                                                                    
 expectations concerning potential restructuring of our business model, including a potential divestiture or closing of our DNA Tagging 
 and Security Products and Services business segment and/or MDx Testing Services segment;                                               |

| · | our expectations of when         
 or if we will become profitable; |

| · | our current non-compliance                                                                                                         
 with Nasdaq's Bid Price Rule, which in the absence of a reverse split, may lead to delisting, potentially negatively impacting our 
 business, our ability to raise capital, and the market price and liquidity of our Common Stock;                                    |

| · | the risk that our LDTs                                                                                                              
 may become subject to additional regulatory requirements due to FDA rulemaking activity, and that compliance with such requirements 
 may be expensive and time-consuming, resulting in significant or unanticipated delay; and                                           |

| · | unknown future market demand                                             
 for the Linea Mpox Virus 1.0 Assay and associated mpox testing services. |

Any or all of our forward-looking statements
may turn out to be wrong. They may be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties.
Actual outcomes and results may differ materially from what is expressed or implied in our forward-looking statements. Among the factors
that could affect future results are:

| · | the inherent uncertainties                                                        
 of product development based on our new and as yet not fully proven technologies; |

| · | the risks and uncertainties                                                                                                 
 regarding the actual effect on humans of seemingly safe and efficacious formulations and treatments when tested clinically; |

| · | formulations and treatments                           
 that utilize our Therapeutic DNA Production Services; |

| · | the inherent uncertainties                                                                                                                
 associated with clinical